

Remarks

Claims 1, 4, 10, 15, 26-27, 45-46, 58 and 68 are amended herein. Claim 1 is amended to be in the form requested by Examiner Rawlings. Support for the amendment of claims 4, 27, 45 and 68 can be found throughout the specification, for example at page 5, lines 31-33, page 17, lines 1-10, page 24, lines 3-9, pages 28-30 (such as page 28, lines 31-33, page 33, lines 16-24). Support for the amendment of claim 10 can be found throughout the specification, for example, in Fig. 1 and SEQ ID NO: 13. Claims 15, 46 and 68 are amended to be in independent form. Claim 20 is amended to correct form, as requested by Examiner Rawlings. Claim 26 is amended as suggested in the Office action dated February 16, 2005; support for this amendment can be found throughout the specification such as on page 28, lines 19-21. Support for the amendment of claim 58 can be found throughout the specification, for example at page 28-33.

Applicants believe no new matter is added herein. Entry of this amendment and reconsideration of the application is respectfully requested.

Telephone Interview

Applicants thank Examiner Rawlings for the very helpful interviews of July 21, 2005 and August 25, 2005, wherein the sequence listing and the claim amendments set forth herein were discussed. Every effort has been made to comply with the Examiner's suggestions for claim amendments. If any matters remain to be discussed before a Notice of allowance is issued, the Examiner is respectfully requested to contact the undersigned for an additional telephone interview.

Sequence Listing

Applicants thank Examiner Rawlings for his detailed review of the disclosed sequences and the sequence listings. As discussed with the Examiner, Fig. 1 of the present application presents a nucleotide sequence encoding SEQ ID NO: 14. In Fig. 1 of the present application, a C is found at position 199 of the nucleotide sequence encoding SEQ ID NO: 14. Similarly, a C is found at position 199 of the nucleotide sequence encoding SEQ ID NO: 14 presented in both of the parent provisional applications (see the figures). However, the sequence listing submitted with the parent PCT application included a G at position 199.

Applicants note that due to the degeneracy of the genetic code, GGG and GGC both encode glycine. Thus, the nucleic acid set forth as SEQ ID NO: 13 encodes SEQ ID NO: 14 regardless of whether a G or a C is listed at position 199.

However, for clarity, and to comply with the Office communication dated July 25, 2005, the sequence listing has been corrected. Thus, in the replacement sequence listing, SEQ ID NO: 13 is the exact sequence shown in Fig. 1 (a C at position number 199). The sequence set forth as SEQ ID NO: 13 encodes SEQ ID NO: 14. As discussed with the Examiner, the sequence set forth as SEQ ID NO: 13 in the enclosed sequence listing is shown in the figures of the present application, the parent PCT application, and both provisional applications. Applicants believe that the submission of the replacement sequence listing overcomes any objection.


Conclusion

Applicants believe that the pending claims are in condition for allowance. If any matters remain to be discussed before a Notice of Allowance is issued, the Applicants respectfully request an additional interview with Examiner Rawlings.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446